Astraea Therapeutics is a discovery-stage biopharmaceutical company, focused on the discovery and preclinical development of small-molecule therapeutics for the treatment of drug addiction and central nervous system disorders.

Astraea’s research and development pipeline consists of lead optimization programs for discovering drug candidates against major molecular targets important for the treatment of CNS disorders, particularly drug addiction and pain. The molecular targets under study are particularly promising for the treatment of addiction to cocaine, alcohol as well as nicotine, all three areas of high unmet clinical need and underrepresented in the pharmaceutical industry. In addition, these targets also have therapeutic potential in other CNS disorders such as neuropathic pain, Parkinson’s disease (therapy-induced dyskinesias), as well as general sedative analgesia, areas that would benefit tremendously from new approaches for treatment.

Astraea’s portfolio highlights the value of our research-based approaches to solve difficult therapeutic problems in areas of critical clinical needs unmet by the pharmaeceutical industry.

Astraea In The News

320 Logue Avenue, Suite 142, Mountain View, CA 94043
Tel: 650-254-0786; Fax: 650-254-0787

Dr. Nurulain Zaveri
President, Chief Scientific Officer